Imigran Subject (Sumatriptan)

Sumatriptan acts as an agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve fibers. This dual action causes vasoconstriction of dilated cranial arteries and blocks the release of inflammatory neuropeptides, interrupting the migraine pain pathway.

The prescribed dose of Imigran is determined by the treating physician based on the patient’s clinical condition, severity of the migraine attack, and prior response to therapy. The prescriber will decide the exact amount and frequency of administration.

The safety of sumatriptan in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Imigran product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Imigran (sumatriptan) belongs to the triptan class, which provides targeted serotonin receptor activation for rapid migraine relief. Compared with non‑specific analgesics, triptans address the underlying vascular and neurogenic mechanisms of migraine, often achieving faster and more complete symptom resolution. Alternative triptans or newer gepants may differ in onset, duration, and side‑effect profiles.

Imigran should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain drug stability and efficacy.

Imigran is supplied as a sterile solution for subcutaneous injection. The injection is typically given into the outer thigh or abdomen using a pre‑filled syringe, following the dosing instructions provided by the prescribing clinician.

Serious risks include chest pain or myocardial ischemia, severe hypertension, serotonin syndrome when combined with other serotonergic agents, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Imigran is contraindicated in individuals with a history of coronary artery disease, uncontrolled hypertension, severe peripheral vascular disease, known hypersensitivity to sumatriptan or any formulation component, and in patients currently taking ergot alkaloids or monoamine oxidase inhibitors.